Adaptimmune Therapeutics Reveals Wenyong Wang Joining As VP Of Business Development

Adaptimmune Therapeutics PLC ADAP disclosed Wenyong Wang has joined the company as its VP of Business Development. The company stated he brings in a vast experience of licensing, collaborations, M&A, tactical partnerships and business development initiatives with an objective on cancer immunotherapy.

Adaptimmune Therapeutics said that before joining, Wang was the MD of Investment Banking at Evolution Life Science Partners. He leveraged his science expertise in offering guidance to pharmaceutical, as well as, biotech clients that sought to improve their portfolios to grow their businesses.

The company's COO, Helen Tayton-Martin, said, "Wenyong combines deep scientific knowledge with strong commercial acumen, and we are delighted that he has joined Adaptimmune. We are confident that his significant expertise will augment the skills of our existing commercial team and add real value as the company pursues an expanding range of business development opportunities."

Similarly, Wang reacted by saying, "I am very pleased to join Adaptimmune at this exciting time. The company has already made great progress and I look forward to working with the rest of the team to contribute to its next growth phase."

Adaptimmune shares closed higher by 1.58 percent on Friday.